Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone‐ and buprenorphine‐maintained subjects

• Published in: British journal of clinical pharmacology Vol. 73; no. 5; pp. 786 - 794
• Main Authors: Gelston, Eloise A., Coller, Janet K., Lopatko, Olga V., James, Heather M., Schmidt, Helmut, White, Jason M., Somogyi, Andrew A.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.05.2012; Blackwell; Blackwell Science Inc
• Subjects: Adolescent; Adult; Analgesics, Opioid - pharmacology; Biological and medical sciences; buprenorphine; Buprenorphine - pharmacology; Codeine - pharmacokinetics; codeine metabolism; CYP2D6 inhibition; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Drug Metabolism; Female; Genotype; glucuronidation inhibition; Glucuronosyltransferase - antagonists & inhibitors; Humans; Male; Medical sciences; methadone; Methadone - pharmacology; Middle Aged; Pharmacology. Drug treatments; Statistics as Topic; Young Adult; Human; Drug; UDP-glucuronosyltransferase; CYP2D6 inhibition; Enzyme; Isozyme; Transferases; Cytochrome P450; glucuronidation inhibition; Glycosyltransferases; Immunoglobulin receptor; 2B4 receptor; Opiates; Glucuronic acid conjugation; Antitussive agent; Methadone; Narcotic analgesic; In vivo; Buprenorphine; codeine metabolism; Hexosyltransferases; Inhibitor; Pharmacokinetics
• ISSN: 0306-5251; 1365-2125; 1365-2125
• DOI: 10.1111/j.1365-2125.2011.04145.x

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Although not well recognized, methadone inhibits CYP2D6 in vivo and in vitro and UGT2B7 and 2B4 in vitro. • We aimed to investigate the effect of methadone on the pathways of codeine metabolism, namely O‐demethylation (CYP2D6), 6‐glucuronidation (UGT2B4/7) and N‐demethylation (CYP3A4/2C8), in subjects maintained on methadone or buprenorphine as a control. WHAT THIS STUDY ADDS • Compared with subjects on buprenorphine, methadone reduced the clearance of codeine to morphine and to codeine‐6‐glucuronide but had no effect on norcodeine formation. • Plasma morphine concentrations remained unchanged, as although its formation was reduced, its metabolism to M3G and M6G was also reduced. • Metabolic drug interactions with methadone cannot assume substrate‐dependent inhibition. AIMS To compare the O‐demethylation (CYP2D6‐mediated), N‐demethylation (CYP3A4‐mediated) and 6‐glucuronidation (UGT2B4/7‐mediated) metabolism of codeine between methadone‐ and buprenorphine‐maintained CYP2D6 extensive metabolizer subjects. METHODS Ten methadone‐ and eight buprenorphine‐maintained subjects received a single 60 mg dose of codeine phosphate. Blood was collected at 3 h and urine over 6 h and assayed for codeine, norcodeine, morphine, morphine‐3‐ and ‐6‐glucuronides and codeine‐6‐glucuronide. RESULTS The urinary metabolic ratio for O‐demethylation was significantly higher (P= 0.0044) in the subjects taking methadone (mean ± SD, 2.8 ± 3.1) compared with those taking buprenorphine (0.60 ± 0.43), likewise for 6‐glucuronide formation (0.31 ± 0.24 vs. 0.053 ± 0.027; P < 0.0002), but there was no significant difference (P= 0.36) in N‐demethylation. Similar changes in plasma metabolic ratios were also found. In plasma, compared with those maintained on buprenorphine, the methadone‐maintained subjects had increased codeine and norcodeine concentrations (P < 0.004), similar morphine (P= 0.72) and lower morphine‐3‐ and ‐6‐ and codeine‐6‐glucuronide concentrations (P < 0.008). CONCLUSION Methadone is associated with inhibition of CYP2D6 and UGTs 2B4 and 2B7 reactions in vivo, even though it is not a substrate for these enzymes. Plasma morphine was not altered, owing to the opposing effects of inhibition of both formation and elimination; however, morphine‐6‐glucuronide (analgesically active) concentrations were substantially reduced. Drug interactions with methadone are likely to include drugs metabolized by various UGTs and CYP2D6.